The landmark ATHENA clinical study helped shape our understanding of the role of high-risk HPV testing in cervical cancer screening
Request copies of the clinical research manuscripts.
Conclusion: Individual detection of HPV 16 in women with ASC-US cytology identifies those women who are at the highest risk of cervical precancer.2
Conclusion: Women with ASC-US cytology who are HPV 16+ could benefit from intensive follow-up in the case of an unsatisfactory colposcopy result.2
The performance of the cobas® HPV Test is comparable to that of the prior standard of testing for pooled high-risk HPV, while adding the benefit of providing genotyping results for the highest-risk genotypes, HPV 16 and 18.
*hc2 and Hybrid Capture 2 is a trademark of Qiagen.
|Result (%)||cobas® HPV Test||hc2 Test|
|Point estimate||(95% CI)||Point estimate||(95% CI)|
|Sensitivity||90.0 (72/80)||(82,95)||87.2 (68/78)||(78,93)|
|Specificity||70.5 (1,056/1,498)||(68,73)||71.1 (1,056/1,485)||(69,73)|
|NPV||99.2 (1,056/1,064)||(98.6,99.6)||99.1 (1,056/1,066)||(99.9,99.5)|
PPV = positive predictive value; NPV = negative predictive value
Hear more from the experts on the implications of the ATHENA HPV trial.
1. American Society for Colposcopy and Cervical Pathology. HPV genotyping clinical update. www.asccp.org. Accessed August 9, 2011.
2. Stoler MH, Wright TC, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-475.
3. cobas® 4800 HPV Test US package insert. April 2011.
4. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens CM, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136:578-586.